Gene therapy vectors based on mammalian promoters offer the potential for increased cell specificity and may be less susceptible than viral promoters to transcription attenuation by host cytokines. The human cytokeratin 18 (K18) gene is naturally expressed in the lung epithelia, a target site for gene therapies to treat certain genetic pediatric lung diseases. Our original vector based on the promoter and 5Ј control elements of K18 offered excellent epithelial cell specificity but relatively low expression levels compared with viral promoters. In the present study, we found that adding a stronger SV40 poly(A) signal boosted primary rat lung epithelial cell expression but greatly reduced cell specificity. Addition of a 3Ј portion of the K18 gene to our vector as a 3Ј untranslated region (UTR) improved epithelial cellspecific expression by reducing expression in lung fibroblasts. The effect of the 3Ј UTR was not related to gross differences in cell-specific splicing. A deletion variant of this UTR further increased lung epithelial cell expression while retaining some cell specificity. These data illustrate the possibilities for using 3Ј UTR to regulate cell-specific transgene expression. Our improved K18 vector should prove useful for pediatric lung gene therapy applications. The epithelial surface of the airways presents an attractive opportunity for the topical delivery of gene-based treatments for pediatric lung diseases. CF and ␣ 1 -antitrypsin deficiency, the two most common fatal monogenic lung disorders in the Caucasian population, have garnered much attention as possible targets for lung gene therapy (1, 2). Other lung disorders that may someday benefit from gene therapies include genetic surfactant protein B deficiency (3) and inflammatory lung diseases (2). CF is caused by a defect in the gene encoding CFTR, a chloride channel residing in the epithelium of the lungs and other organs (4, 5). CF affects multiple organ systems, but it is the lung disease, characterized by thick mucous, persistent bacterial infection, and inflammation, that causes the majority of morbidity and mortality associated with CF (5, 6). In theory, early intervention to deliver a functional CFTR gene to just 5 to 10% of the defective lung cells of CF patients could lead to an improvement in the lung airway surface fluid and an improved prognosis (7, 8) . Attempts at human gene therapy proved the feasibility of this approach (9), but challenges remain before CF gene therapy becomes a reality.
The epithelial surface of the airways presents an attractive opportunity for the topical delivery of gene-based treatments for pediatric lung diseases. CF and ␣ 1 -antitrypsin deficiency, the two most common fatal monogenic lung disorders in the Caucasian population, have garnered much attention as possible targets for lung gene therapy (1, 2) . Other lung disorders that may someday benefit from gene therapies include genetic surfactant protein B deficiency (3) and inflammatory lung diseases (2) . CF is caused by a defect in the gene encoding CFTR, a chloride channel residing in the epithelium of the lungs and other organs (4, 5) . CF affects multiple organ systems, but it is the lung disease, characterized by thick mucous, persistent bacterial infection, and inflammation, that causes the majority of morbidity and mortality associated with CF (5, 6) . In theory, early intervention to deliver a functional CFTR gene to just 5 to 10% of the defective lung cells of CF patients could lead to an improvement in the lung airway surface fluid and an improved prognosis (7, 8) . Attempts at human gene therapy proved the feasibility of this approach (9) , but challenges remain before CF gene therapy becomes a reality.
Viral vectors such as those derived from human adenovirus can efficiently deliver DNA to cells, but host immune responses to both the virus and transgene are problematic (10, 11) . Complexes of DNA and cationic liposome have been widely tested and have the advantages of relatively low toxicity, low immunogenicity, and ease of preparation (12) but are currently inefficient as DNA delivery vehicles (13, 14) . It may be possible to counter this problem by choosing a strong expression vector to drive the production of CFTR. It may also be desirable to have expression that is long-lasting, which could lower the frequency of applications, reducing both adverse effects and expense. Controlling the cell specificity of CFTR expression could be important for reducing gene therapy side effects. In the lung, CFTR is expressed in the airway epithelial and submucosal gland cells (15) . Inappropriate CFTR expression in cultured cells can cause growth abnormalities (16, 17) , but clinical effects, if any, are not known.
To maximize gene expression, many gene therapy vectors use strong viral promoters such as the widely used CMV immediate-early promoter/enhancer (18) . Although high expression levels can be achieved in cultured cells by use of viral promoters, they may not be a good choice for sustained gene expression for lung gene therapy. It has been shown that transcription from viral promoters, including CMV, is downregulated by host cytokines such as IFN-␥ and TNF-␣ in a phenomenon known as "promoter attenuation" (19) . These cytokines are induced by adenoviral and DNA:liposome gene therapy delivery systems (20, 21) .
We sought to avoid these pitfalls and improve the duration and specificity of transgene expression both in vitro and ultimately in vivo by using a nonviral promoter naturally active in lung epithelial cells. Human K18 is expressed specifically in the epithelial cells of internal organs (22) . Its expression is regulated by positive and negative elements upstream of the promoter and in the first intron and exon 6 (23) (24) (25) . Using a vector constructed with the K18 promoter, first intron, and upstream regulatory elements, we were able to drive epithelialspecific gene expression in transgenic mice and in transiently transfected cultured human cells (26) . Although our firstgeneration K18 vector demonstrated promising long-term transgene expression and excellent epithelial cell specificity in cultured human cells, short-term expression was low in relation to a CMV-based vector. In the present study, we have improved the level of expression from our K18-based vector while retaining its epithelial cell specificity through the use of a 3Ј UTR derived from K18.
METHODS
Plasmids. pK18SEAP-EpA was previously described as K18EpilongSEAP (26) and contains the promoter and 2.5-kb upstream genomic sequence from the human K18 gene plus the first intron of K18, before the start of the SEAP gene (pSEAP, Tropix, Bedford, MA, U.S.A.). pCMVSEAP-EpA was constructed by cloning the CMV immediate-early promoter/ enhancer from pCEP4 (Invitrogen) into pSEAP. After the SEAP gene, both these vectors include the SV40 t intron and SV40 minimal (237 nt) early poly(A) signal. These were replaced with the SV40 late poly(A) signal from pMP6a (27) (originally from pREP4, Invitrogen, Carlsbad, CA, U.S.A.) to create pK18SEAP-LpA and pCMVSEAP-LpA.
A 1-kb region of the K18 gene from nucleotides 5521-6520, referred to here as K18 native 3Ј (or K18n3Ј), was PCR cloned from human genomic DNA. This region comprises K18 exon 6, intron 6, exon 7, and 272 nt of untranslated downstream sequence including the K18 poly(A) signal. When added to our SEAP vectors, replacing the SV40 poly(A) signal, this DNA segment functioned as a 3Ј UTR with a K18 poly(A) signal. Deletions of this region were constructed as depicted in Figure  3A , using the KpnI and PmlI restriction sites indicated.
pK18mTElacZ-K18i6x7pA was created by removing the SV40 medium-length (512 nt) early poly(A) signal of pK18mTElacZ (26) and replacing it with the K18i6x7pA UTR. The parental K18 vector contained a mutation (m) of the K18 first intron 3Ј splice acceptor site to reduce exon skipping events and a translational enhancer (TE) sequence from alfalfa mosaic virus (28) placed immediately upstream of the lacZ start codon (26) . The bacterial ␤-galactosidase gene included a 5Ј nuclear localization signal (NLS) from the SV40 large T protein. pMP6aTElacZ was created by inserting the TE and ␤-galactosidase gene of pK18mTElacZ into the multicloning site of pMP6a (27) .
pK18mTECFTR-K18i6x7pA was created by removing the SV40 minimal early poly(A) signal of pK18mTECFTR (26) and replacing it with the -K18i6x7pA UTR. The parental K18 vector contains the K18 first intron mutation and TE mentioned above. Additionally, a silent mutation was placed in the CFTR cDNA to eliminate cryptic splicing events documented between K18 intron 1 and CFTR (26) . Epitope-tagged versions of 
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OPTIMIZED LUNG GENE THERAPY VECTOR these vectors were created by using a CFTR cDNA that had the VSV-G coding sequence added to place the tag at the protein's C-terminus (pCFTag, Z. Lu). To correct the splicing defect arising from a cryptic 5Ј donor site in the VSV-G coding sequence, this sequence was changed from TACACCGA-CATCGAGATGAACCGGCTGGGCAAG to TACACCGACATCGAGATGAACCGGCTtGGgAAa by mutagenic primer PCR.
Tissue culture and reporter gene assays. COS-1 and A549 cells were maintained as recommended by the American Type Culture Collection. Primary cultures of rat lung epithelial and fibroblast cells were isolated from gestational d 19 -20 rat fetuses and maintained in culture as described (29) . Cell populations isolated using this method are approximately 90% pure (29, 30) . One day after isolation, 0.5 ϫ 10 6 cells were seeded per 35-mm well in a 6-well plate and were transfected 18 h later (at 50 to 80% confluence) with 1 g of plasmid DNA premixed with 12 g of lipofectAMINE (as recommended by the manufacturer, GIBCO/BRL, Rockville, MD, U.S.A.) in duplicate culture wells. Cell cultures became confluent and contact growth-inhibited by the first assay point (2 d posttransfection). The 2-mL culture medium was changed 24 h before each assay point. The 24-h accumulation of SEAP activity was assayed in 30 L of media by using the Phospha-Light chemiluminescent system (Tropix, Bedford, MA, U.S.A.) and measured on a microplate luminometer (E.G.&G. Berthold LB96V, Bad Wildbad, Germany). Data are expressed as thousands of relative light units after subtracting a negative control. To correct for variation in the transfection capacity of different batches of primary cells, pCMVSEAP was used as a transfection control in separate duplicate culture wells (we found that using internal control plasmids caused distortion of the data). Each data set from different cell batches was then normalized to the average value for pCMVSEAP expression at 2 d posttransfection (the first time point assayed) for that cell batch.
␤-galactosidase activity in cell lysates was assayed using the Galacto-Light chemiluminescent system (Tropix) and measured on a microplate luminometer (E.G.&G. Berthold LB96V). Values are expressed as thousands of relative light units after normalizing for lysate protein content and subtracting a negative control.
Reverse transcriptase-PCR (RT-PCR) and Western blot. Total RNA was isolated from cells 3 d after transfection, treated with DNaseI to remove residual plasmid DNA, repurified, and reverse transcribed with the primer ATTGGCCTC-CTGCTCCCAAAGG in the K18n3Ј region [after exon 7 and before the poly(A) cleavage site]. PCR to detect splicing of K18 intron 6 in pK18SEAP-K18n3Ј was performed with the primer GAAACGGTCCAGGCTATGTGCTC in the SEAP coding region and GGTGTCATTGGTCTCAGACACCAC in the K18n3Ј region.
Whole lysates of COS-1 cells were prepared in RIPA buffer as described (31) 48 h after transfection with CFTR vectors. After SDS/PAGE of cell extracts containing 100 g of total protein per lane and Western transfer, the blot was probed with the C-terminus-specific CFTR MAb L12B4 (32) .
RESULTS
Polyadenylation signals and cell specificity. As suggested from earlier work with cell lines (26), our K18-based vectors demonstrated excellent long-term transgene expression in primary rat pneumocytes (Fig. 1) . Replacing the SV40 minimal early poly(A) signal with the SV40 late poly(A) signal in both K18-and CMV-based vectors increased SEAP expression greatly, as expected (33) . In epithelial cells, changing the poly(A) signal increased gene expression up to 8-fold for the CMV-based vector and approximately 40-fold for the K18-based vector. In fibroblasts, changing the poly(A) signal increased expression up to 15-fold for the CMV-based vector but up to 100-fold for the K18-based vector. This resulted in a large relative decrease in epithelial cell specificity of the K18-based vector. In preliminary experiments, we found that using either the SV40 full-length early (988 nt) or bovine GH poly(A) signals with the K18-based vector resulted in levels of transgene expression similar to that of the SV40 late poly(A) signal, with a similar loss of epithelial cell specificity.
A 3 region of human K18 enhances epithelial cell specificity. We tested a 3Ј genomic region of the human K18 gene comprising exon 6, intron 6, exon 7, the poly(A) signal, and 3Ј flanking sequence for its effect on expression and cell specificity. This region was selected because it contains control elements found in exon 6 of the K18 gene (25) . We added it to our K18 vector as a 3Ј UTR, replacing the viral poly(A) signal, to mimic the 3Ј structure of the natural human K18 transcription unit. When this region (n3Ј) was added, epithelial cell expression was comparable in level and duration to the K18 vector with the SV40 late poly(A) signal whereas fibroblast expression was reduced, and this difference increased at later times after transfection (Fig. 2, A and B) . The K18n3Ј UTR also improved the epithelial cell specificity of a CMV-based vector ( Fig. 2A) .
To determine whether the reduction in fibroblast expression was due to events occurring before or after transcription, we placed an SV40 late poly(A) signal upstream of the K18 n3Ј region (but downstream of SEAP) in our K18 vector. This is expected to eliminate any effects of RNA sequences downstream of the viral poly(A) signal after polyadenylation processing. When the viral poly(A) signal preceded the K18 n3Ј region, expression was similar to that of the SV40 late poly(A) signal alone in both epithelial and fibroblast cells (Fig. 2B) . These data suggest that the effect of the unencumbered K18 n3Ј region on reducing expression in fibroblasts is due to events occurring after transcription.
Deletions of the K18 n3 UTR. We performed deletions of the K18 n3Ј UTR (Fig. 3A) to identify the region(s) responsible 
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for reducing transgene expression in fibroblasts. K18 exon 6 was of particular interest because it contains a DNaseI hypersensitive region and AP-1 binding site. Deleting intron 6 and exon 7 to leave exon 6 and the K18 poly(A) signal (-K18x6pA) resulted in a similar level of epithelial expression compared with the K18 poly(A) signal alone and a reduction in fibroblast expression at later times (Fig. 3B ). Deleting exon 6 to leave intron 6, exon 7, and the K18 poly(A) signal (-K18i6x7pA) resulted in a 4-fold increase in epithelial expression in the first 3 d compared with -K18n3Ј and a pattern of fibroblast expression similar to that of -K18x6pA. When we replaced the SV40 late poly(A) signal of a CMV-based vector with the -K18i6x7pA UTR, expression in lung epithelial cells doubled whereas fibroblast expression was halved (data not shown).
Effect of intron 6 splicing on transgene expression. Although the -K18x6pA and -K18i6x7pA constructs together contain all the DNA sequences present in K18n3Ј, the total decrease in fibroblast expression (relative to pK18SEAP-LpA) seen with both vectors is less than half that seen with the intact K18n3Ј (Fig. 3B) . Because only the intact K18n3Ј has a spliceable intron 6, we sought to examine the role of cellspecific RNA splicing differences on the effect of the K18n3Ј on cell-specific gene expression. RT-PCR of rat pneumocytes transfected with the K18 vector containing the K18n3Ј UTR revealed that the correctly spliced product was produced in both epithelial and fibroblast cells (Fig. 4) .
Addition of K18i6x7pA 3 UTR to other expression vectors. Based on the knowledge gained from our SEAP reporter gene work, we tested the effect of the K18i6x7pA UTR on the expression characteristics of our K18-based lacZ and CFTR expression vectors. Because both lacZ (34) and CFTR contain potential cryptic 5Ј donor sequences in the 3Ј regions of their cDNA and the K18i6x7pA UTR contains the 3Ј splice acceptor site of intron 6, there existed a possibility for disruptive cryptic splicing. We, therefore, used RT-PCR to examine the RNA from COS, A549, and primary rat pneumocytes transfected with our K18 lacZ and CFTR vectors. These vectors had no aberrant splicing events in any of the tested cell types (not shown). However, addition of a VSV-G epitope-tagged CFTR sequence to our K18i6x7pA UTR vector produced a destructive splicing event between the sequences coding for the VSV-G tag and the 3Ј splice acceptor site of K18 intron 6. Silent mutagenesis of the VSV-G coding sequence to eliminate the cryptic 5Ј splice donor sequence successfully eliminated the splicing problem (data not shown).
The vector pK18mTElacZ-K18i6x7pA had improved ␤-galactosidase expression compared with its parental vector pK18mTElacZ (Fig. 5A) . Expression was enhanced up to 6-fold in epithelial cells and up to 2-fold in fibroblasts, resulting in increased epithelial cell specificity. The increase in fibroblast expression relative to pK18mTElacZ is an apparent discrepancy with the SEAP data regarding the K18i6x7pA UTR (Fig. 3B ). This is due to the fact that the parental vector pK18mTElacZ does not contain the SV40 late poly(A) signal but the weaker SV40 medium-length early poly(A) signal. Compared with the strong expression vector pMP6aTElacZ [based on pMP6a (27) ], which contains a CMV promoter/ enhancer, hybrid intron, and SV40 late poly(A) signal, our new pK18mTElacZ-K18i6x7pA vector demonstrated excellent expression in lung epithelial cells with substantially reduced fibroblast expression. In contrast with our work with the SEAP reporter gene, we consistently observed higher levels of lacZ expression in fibroblasts versus epithelial cells with all expression vectors. We and others (35) have noticed that, in general, cationic liposomes tend to transfect fibroblasts more readily than epithelial cells. However, the same liposome (lipofectAMINE) was used in both reporter gene studies. The difference could be related to cell-specific differences in the processing of the two protein products (SEAP is continually excreted whereas the ␤-galactosidase we used is NLS-targeted to the nucleus). Alternatively, because the lacZ vectors tested are approximately 20% larger than the SEAP vectors, lung fibroblasts may be more transfectable with the larger DNA constructs than epithelial cells.
We also tested the ability of the K18i6x7pA UTR to improve our original K18-based CFTR vector (26) . Although Western blot is a semiquantitative assay, it appears that a greater amount of mature CFTR protein was produced by pK18mTECFTR-K18i6x7pA than was produced by the original K18 CFTR vector (Fig. 5B) .
DISCUSSION
We have developed expression vectors using control elements from the human K18 gene, which is naturally active in lung epithelial cells (22) . Our original human K18-based vector offered highly specific and long-lasting epithelial expression in transgenic mice, human cell lines (26) , and primary rat pneumocytes (this study), yet expression was relatively low compared with viral promoters. Polyadenylation is a crucial step in RNA processing, mRNA stability, and ultimately gene expression. Because the SV40 minimal early poly(A) signal of our original K18 vector is relatively weak, we replaced it with the strong SV40 late signal. Epithelial cell gene expression was substantially enhanced, but expression in fibroblasts was further increased, resulting in a reduction in epithelial cell specificity. This may reflect differences between epithelial cells and fibroblasts in the responses of their cellular polyadenylation machinery to different viral poly(A) signals.
Exon 6 of the human K18 gene contains a DNaseI hypersensitive region and a functional AP-1 binding site and may be involved in regulating native K18 gene expression (25) . We, therefore, tested whether a 1-kb 3Ј genomic fragment of this gene (K18n3Ј), including exon 6, could improve the expression characteristics of our K18 vector. We added this region as a 3Ј UTR to mimic the 3Ј structure of the natural K18 transcription unit. A similar approach was successfully developed by Low et al. (36) , who used a 3Ј region of the hGH gene as a 3Ј UTR to direct gonadotrophic cell-specific expression in transgenic mice. Replacement of the hGH 3Ј region with an SV40 poly(A) signal resulted in a loss of gonadotroph-specific expression. We found that addition of the K18n3Ј UTR to our K18 vector reduced lung fibroblast expression, resulting in an improvement in epithelial cell specificity (up to 11-fold at later times after transfection) compared with the SV40 late poly(A) signal. Lung epithelial cell expression was comparable in level and duration to the K18 vector with the SV40 late poly(A) signal. This effect was also seen to a lesser degree in a CMV-based vector, indicating that the effect is partially independent of the 5Ј control elements of our K18 vector.
Untranslated 3Ј regions can influence gene expression through DNA-and RNA-mediated mechanisms and effects on RNA translation. Deletion analysis of the K18n3Ј UTR indicated that it contains both positive and negative regulatory elements for transgene expression in lung pneumocytes. Neznanov et al. (25) found that the AP-1 site in exon 6 had a positive effect on expression in F9 embryonic carcinoma cells but not in HR9 endoderm cells. We found that the exon 6 region combined with the K18 poly(A) signal decreased expression in lung fibroblasts but not in epithelial cells compared with the vector with the K18 poly(A) signal alone. In the absence of exon 6 (K18i6x7pA), lung fibroblast expression was similarly decreased, whereas epithelial expression was enhanced. However, we added the K18 downstream elements to our vectors as a UTR to mimic the structure of the human K18 transcription unit, whereas Neznanov et al. (25) added exon 6 upstream of the K18 promoter to test AP-1 responsiveness. It appears that the K18n3Ј in our vectors, tested in lung cells, does not act at the DNA level, though. Expression from plasmids with an SV40 poly(A) signal was not affected by the downstream presence of the K18n3Ј. This also argues against DNA-mediated enhancer/silencer effects or gross differences in 
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If mRNA is improperly spliced, the presence of an intron can lead to RNA degradation and lower gene expression (37) . We hypothesized that perhaps incorrect splicing of K18 intron 6 in lung fibroblasts was responsible for the reduction in reporter gene activity due to the K18n3Ј UTR. However, RT-PCR of rat pneumocytes revealed that the K18n3Ј UTR was correctly spliced in transfected epithelial and fibroblast cells. Even spliced correctly, the K18n3Ј UTR may act to preferentially reduce the half-life of the mRNA in lung fibroblasts, but this hypothesis remains a topic for future studies.
Using the knowledge gained from our SEAP reporter gene work, we tested the effect of the K18i6x7pA 3Ј UTR on the expression from our other K18-based vectors. This UTR offers a useful combination of decreased fibroblast expression (up to 4-fold) and enhanced epithelial cell expression (up to 3-fold) compared with the SV40 late poly(A) signal. A lacZ vector incorporating the K18i6x7pA UTR demonstrated improved epithelial expression and specificity compared with our original (26) K18-based lacZ vector or a strong CMV-based vector. Addition of the K18i6x7pA UTR to our K18-based CFTR vector also proved promising.
In this study, we demonstrated that changing polyadenylation signals of an epithelial-specific human K18-based vector to improve expression levels can have significant effects on cell specificity. We found that a strategy of using additional control elements from K18 as a 3Ј UTR was successful in producing high-level epithelial cell expression with good cell specificity. Our new generation K18-based vectors may prove useful for maximizing transgene expression and specificity for gene therapy to treat certain pediatric lung disorders. Although we have focused here on the DNA:liposome delivery route, our expression cassette could be adopted for use with other, possibly more efficient, delivery systems including the latest viral vectors and nonviral strategies that use receptor-mediated endocytosis.
